FREENOME: REVOLUTIONIZING
EARLY CANCER DETECTION WITH
AI-POWERED BLOOD TESTS
THE FUTURE OF CANCER
SCREENING Where Every Life Matters
Potential Impact:
Saves 30–50% of cancer patients
through early intervention.
Provides scalable, accessible
diagnostics. FREENOME
Limitations:
High computational resource CONTACT US
demand. Ready to embark on a journey of digital
Currently limited cancer type transformation? Connect with us today!
detection.
844-625-0976
Image of a futuristic AI interface
www.freenome.com
analyzing blood samples.
Subtle overlay of DNA helixes
and molecular patterns.
[email protected] “Learn how Freenome is transforming
cancer screening and saving lives.”
279 East Grand Avenue 5th Floor
South San Francisco, CA 94080
Regulatory Compliance and Quality Benefits:
GCP & Health Canada Standards: Detects cancer 1–3 years earlier.
Reduces invasive procedures by
up to 40%.
1. Adheres to ICH E6(R2) guidelines for
Advantages:
Good Clinical Practice. High data accuracy.
2. Compliant with Health Canada's Rapid and scalable analysis.
Medical Devices Regulations. Reliable and reproducible results.
3. Ensures patient safety, data
integrity, and privacy.
Quality Assurance (QA) Benefits:
1. Automated error checks.
2. Consistent algorithmic
interpretation. t
Freenome combines AI and machine
learning to analyze cell-free DNA and
biomarkers for early cancer detection.
Key Uses:
Screening for colorectal cancer.
Minimally invasive diagnostic
methods.
Identifying cancerous signals before
tumor formation.
